Robles-Zurita, José
Boyd, Kathleen A.
Briggs, Andrew H.
Iveson, Timothy
Kerr, Rachel S.
Saunders, Mark P.
Cassidy, Jim
Hollander, Niels Henrik
Tabernero, Josep
Segelov, Eva
Glimelius, Bengt
Harkin, Andrea
Allan, Karen
McQueen, John
Pearson, Sarah
Waterston, Ashita
Medley, Louise
Wilson, Charles
Ellis, Richard
Essapen, Sharadah
Dhadda, Amandeep S.
Hughes, Rob
Falk, Stephen
Raouf, Sherif
Rees, Charlotte
Olesen, Rene K
Propper, David
Bridgewater, John
Azzabi, Ashraf
Farrugia, David
Webb, Andrew
Cunningham, David
Hickish, Tamas
Weaver, Andrew
Gollins, Simon
Wasan, Harpreet S
Paul, James
Funding for this research was provided by:
Medical Research Council (G0601705)
Cancer Research UK (C6716/A9894)
The Study Sponsor was NHS Greater Glasgow & Clyde and University of Glasgow
Article History
Received: 6 April 2018
Revised: 3 October 2018
Accepted: 9 October 2018
First Online: 13 November 2018
Competing interests
: T.I. reports Honoraria from Lilly Advisory Boards for Servier, Roche and Celgene Travel expenses from Bayer and Servier outside the submitted work. J.B. reports personal fees from Servier, Celgene and Merck, and non financial supports from Merck Sharpe and Dohme outside the submitted work. C.W. reports grants from sirtex-european symposium Nov 2016, outside the submitted work. D.C. reports grants from Amgen, AstraZeneca, Bayer, Celgene, Merrimack, MedImmune, Merck Serono and Sanofi, outside the submitted work. J.C. reports grants from MRC and CRUK, and confirms that he is currently an employee with Celgene Corporation. K.A.B. reports grants from Medical Research Council during the conduct of the study. J.T. reports other from Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Symphogen, Taiho and Takeda, outside the submitted work. A.W. is involved in research that is funded by drug companies that provide the drugs for the study. She has been co-investigator in trials funded by Roche that provide Capecitabine used in this study. B.G. sits on the Advisory Board for PledPharma AB.
: This study was approved by the West Glasgow Research Ethics Committee (version 1.1 of the protocol) on 21st January 2008 and all subsequent amendments approved by the Committee (where required). REC reference number: 07/S0703/136.